LiteVax BV is a biopharmaceutical company dedicated to the development and exploitation of novel human vaccine adjuvant products.
Our lead adjuvant candidate outperforms commercially available alternatives by delivering superior efficacy with minimal toxicity, enabling the production of vaccines at significantly reduced costs and facilitating effective single-dose applications.
Currently, we are in the clinical development phase, having initiated a second clinical trial in February 2024, aimed at enhancing influenza vaccines for the elderly population.
